Literature DB >> 8643099

Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein.

M A Roggero1, B Filippi, P Church, S L Hoffman, U Blum-Tirouvanziam, J A Lopez, F Esposito, H Matile, C D Reymond, N Fasel.   

Abstract

We investigated the immunogenicity and the conformational properties of the non-repetitive sequences of the Plasmodium falciparum circumsporozoite (CS) protein. Two polypeptides of 104 and 102 amino acids long, covering, respectively, the N- and C-terminal regions of the CS protein, were synthesized using solid phase Fmoc chemistry. The crude polypeptides were purified by a combination of size exclusion chromatography and RP-HPLC. Sera of mice immunized with the free polypeptides emulsified in incomplete Freund's adjuvant strongly reacted with the synthetic polypeptides as well as with native CS protein as judged by ELISA and IFAT assays. Most importantly, these antisera inhibited the sporozoite invasion of hepatoma cells. In addition, sera derived from donors living in a malaria endemic area recognized the CS 104- and 102-mers. Conformational studies of the CS polypeptides were also performed by circular dichroism spectroscopy showing the presence of a weakly ordered structure that can be increased by addition of trifluoroethanol. The obtained results indicate that the synthetic CS polypeptides and the natural CS protein share some common antigenic determinants and probably have similar conformation. The approach used in this study might be useful for the development of a synthetic malaria vaccine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8643099     DOI: 10.1016/0161-5890(95)00136-0

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  9 in total

1.  Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity.

Authors:  M Theisen; D Dodoo; A Toure-Balde; S Soe; G Corradin; K K Koram; J A Kurtzhals; L Hviid; T Theander; B Akanmori; M Ndiaye; P Druilhe
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

2.  Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies.

Authors:  Diego A Espinosa; Gabriel M Gutierrez; Maricarmen Rojas-López; Amy R Noe; Lirong Shi; Sze-Wah Tse; Photini Sinnis; Fidel Zavala
Journal:  J Infect Dis       Date:  2015-03-11       Impact factor: 5.226

3.  Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate.

Authors:  Matthew L Plassmeyer; Karine Reiter; Richard L Shimp; Svetlana Kotova; Paul D Smith; Darrell E Hurt; Brent House; Xiaoyan Zou; Yanling Zhang; Merrit Hickman; Onyinyechukwu Uchime; Raul Herrera; Vu Nguyen; Jacqueline Glen; Jacob Lebowitz; Albert J Jin; Louis H Miller; Nicholas J MacDonald; Yimin Wu; David L Narum
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

4.  Evidence for multiple B- and T-cell epitopes in Plasmodium falciparum liver-stage antigen 3.

Authors:  Aissatou Toure-Balde; Blanca-Liliana Perlaza; Jean-Pierre Sauzet; Mouhamadou Ndiaye; Georgette Aribot; Adama Tall; Cheikh Sokhna; Christophe Rogier; Giampietro Corradin; Christian Roussilhon; Pierre Druilhe
Journal:  Infect Immun       Date:  2009-01-12       Impact factor: 3.441

5.  The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.

Authors:  Régine Audran; Floriana Lurati-Ruiz; Blaise Genton; Hildur E Blythman; Opokua Ofori-Anyinam; Christophe Reymond; Giampietro Corradin; François Spertini
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

6.  Genetic variation in the Plasmodium falciparum circumsporozoite protein in India and its relevance to RTS,S malaria vaccine.

Authors:  Mohammad Zeeshan; Mohammad Tauqeer Alam; Sumiti Vinayak; Hema Bora; Rupesh Kumar Tyagi; Mohd Shoeb Alam; Vandana Choudhary; Pooja Mittra; Vanshika Lumb; Praveen Kumar Bharti; Venkatachalam Udhayakumar; Neeru Singh; Vidhan Jain; Pushpendra Pal Singh; Yagya Dutta Sharma
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

7.  Sterile protection against malaria is independent of immune responses to the circumsporozoite protein.

Authors:  Anne Charlotte Grüner; Marjorie Mauduit; Rita Tewari; Jackeline F Romero; Nadya Depinay; Michèle Kayibanda; Eliette Lallemand; Jean-Marc Chavatte; Andrea Crisanti; Photini Sinnis; Dominique Mazier; Giampietro Corradin; Georges Snounou; Laurent Rénia
Journal:  PLoS One       Date:  2007-12-26       Impact factor: 3.240

8.  A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein.

Authors:  Joshua Tan; Brandon K Sack; David Oyen; Isabelle Zenklusen; Luca Piccoli; Sonia Barbieri; Mathilde Foglierini; Chiara Silacci Fregni; Jessica Marcandalli; Said Jongo; Salim Abdulla; Laurent Perez; Giampietro Corradin; Luca Varani; Federica Sallusto; Betty Kim Lee Sim; Stephen L Hoffman; Stefan H I Kappe; Claudia Daubenberger; Ian A Wilson; Antonio Lanzavecchia
Journal:  Nat Med       Date:  2018-03-19       Impact factor: 53.440

9.  Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein.

Authors:  Lawrence T Wang; Lais S Pereira; Patience K Kiyuka; Arne Schön; Neville K Kisalu; Rachel Vistein; Marlon Dillon; Brian G Bonilla; Alvaro Molina-Cruz; Carolina Barillas-Mury; Joshua Tan; Azza H Idris; Joseph R Francica; Robert A Seder
Journal:  PLoS Pathog       Date:  2021-12-06       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.